Art has led forecasting engagements in over 200 therapy areas across 61 countries and on six continents.

Art has led several practice area teams within ZS, including forecasting and portfolio strategy. He currently leads the firm’s biosimilars center of excellence, which supports ZS teams in engagements related to biosimilar products.

Art has an extensive range of international forecasting and portfolio optimization experience that has evolved from working on pharmaceutical and healthcare industry issues in North America, South America, Europe, Australia, Asia and Africa. He is the author of the 2015 book Forecasting for the Pharmaceutical Industry and has written articles on forecasting for Pharmaceutical Executive. In addition, he has presented several times at the Pharmaceutical Management Sciences Association and the Pharmaceutical Market Research Group, and has conducted numerous forecast and portfolio management training sessions worldwide.

Before joining ZS, Art’s experience was within the pharmaceutical industry. He was the international director of forecasting, pricing and market research at Roche and the director of sales strategy and analytics at Syntex. Art’s ZS assignments have included work in all the major and “pharmerging” pharmaceutical markets and more than 150 therapeutic areas.

Art holds an MBA from the University of California, Berkeley, a Ph.D. in chemistry from Harvard University and a bachelor’s in chemistry from Stanford University.